DENVER, CO / ACCESSWIRE / November 6, 2018 / Nexien BioPharma Inc. (OTCQB: NXEN) (“Nexien” or the “Company”)
announced that it was initiating an investigation into the use of cannabinoid-based formulations for the treatment of patients
suffering from Myotonic Dystrophy (DM) and Myotonia.
Munich-based Dr. Benedikt Schoser, who joined Nexien as a scientific advisor in July, and myotonic dystrophy patient
organizations, recently shared two questionnaires. One was in Germany and the other in the United States with both DM type 1 and DM
type 2 patients. The purpose of the questionnaires was to determine patient experience with cannabinoids and if cannabinoids